CONTENTS
Issue 84 | July 2019
In association with
The case for and against establishing a nationalised drug company in the UK.
Research into underwater forests is driving hope for new drug discoveries.
Exploring the high-profile runners in the race to be the first NASH drug to market.
What are the therapeutic benefits, risks and market potential of Brexanolone?
How can AI help to reduce the number of clinical trial failures?
Introducing ‘discovery proteomics’ to enhance clinical trials.